Authors
Latest:
Using Brain Connectomes to Predict Disease Progression and Treatment Response in Multiple Sclerosis: Ceren Tozlu, PhDThe instructor in the department of radiology at Weill Cornell Medicine discussed how structural and functional brain connectomes can potentially improve predictions of MS progression and treatment response. [WATCH TIME: 4 minutes]
Latest:
Therapeutic Advantages to Using EEG to Assess Alzheimer Agents: Williem de Haan, MD, PhDThe neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]
Latest:
Therapeutic Focuses of MS and the Need to Reach NEDA Status: Stuart Silverman, MDAs the treatment landscape for relapsing MS continues to strengthen, the neurologist at Allegheny Health Network discussed the reasons for continued pursuit of drug development. [WATCH TIME: 3 minutes]
Latest:
Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MDThe resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]
Latest:
Davangere Devanand, MBBS, MD: Lithium for Agitation in Alzheimer DiseaseThe professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.
Latest:
Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep ApneaRecent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.
Latest:
Jan Hillert, MD, PhD: Stem Cell Transplants in MSThe professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the use of stem cell transplantation as a potential method of treating multiple sclerosis.
Latest:
Danny Eckert, PhD: Pharmacotherapies Reducing OSA SeverityProof-of-concept studies using a targeted phenotypic approach to reduce obstructive sleep apnea severity are showing exciting results.
Latest:
The Evolutionary Arch of Stereoelectroencephalography in the United StatesSEEG has transformed the surgical investigation of refractory epilepsy, enabling clinicians to map complex seizure networks with precision, leading to more targeted treatment options for patients.
Latest:
Alzheimer Disease: Separating Fact from FictionIn honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.
Latest:
Groundbreaking Epilepsy Research Studies on the Horizon in 2023: Anup Patel, MDThe pediatric neurologist at Nationwide Children's Hospital discussed the epilepsy research studies that he is excited about in 2023. [WATCH TIME: 4 minutes]
Latest:
Jeffrey Buchhalter, MD: Disclosing SUDEP Risk to Patients With EpilepsyThe pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how drastically things have changed surrounding the patient-physician conversation about SUDEP.
Latest:
2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MDThe codirector of the Precision Medicine MS Center at Johns Hopkins University discussed the new updates to the MS diagnostic criteria presented at the 40th ECTRIMS Congress in Copenhagen. [WATCH TIME: 5 minutes]
Latest:
Jessica Robinson-Papp, MD: Medical Marijuana for Neurologic ConditionsThe professor of neurology at the Icahn School of Medicine at Mount Sinai spoke about what’s currently known about medical marijuana’s use, how CBD fits into the conversation, and what research still needs to be done.
Latest:
Amy B. Sullivan, PsyD: Screening MS Patients for ComorbiditiesThe director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of screening patients with MS for other conditions for which they are prevalently comorbid, such as depression or sleep disorders.
Latest:
Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DScThe professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]
Latest:
Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MScThe associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]
Latest:
CMSC Live: 2024 Annual Meeting Day 1Host Jeffrey Wilken, PhD, chats with Robert Naismith, MD; Jiwon Oh, MD, PhD; and Anthony Traboulsee, MD, about the first day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.
Latest:
Future Treatment of hATTR AmyloidosisAnalysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
Latest:
Lutz Frolich, MD, PhD: Learning from Negative TrialsLutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.
Latest:
Justifying Use of CGRP mAbs in Pediatric Patients With MigraineWhat happens to the approximately 24% of pediatric patients with migraine who do not respond to the preventive treatments recommended in the AAN guidelines?
Latest:
Jacqueline French, MD: Barriers to Identifying Nonmotor SeizuresThe director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the need to improve education about nonmotor seizures.
Latest:
Amit Rakhit, MD, MBA: Measuring Improvement in Fragile X Syndrome, Other Rare ConditionsThe chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.
Latest:
Andre Machado, MD, PhD: Multidisciplinary Treatment in Movement DisordersThe Chairman of the Neurological Institute at Cleveland Clinic provided insight into the multidisciplinary decision-making process for patients with movement disorders at the center.
Latest:
Therapies for Children and Adults with Dravet SyndromeThe panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.
Latest:
Steps in Translating Genetic Discoveries Into Effective Treatments for ALS: Matthew B. Harms, MDThe associate professor of neurology at Columbia University provided commentary on the rapid advancements in translating genetic research into ALS treatments and the challenges that remain. [WATCH TIME: 5 minutes]
Latest:
Future Treatment of hATTR AmyloidosisAnalysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
